Catalyst Pharmaceuticals Ownership | Who Owns Catalyst Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Catalyst Pharmaceuticals Ownership Summary


Catalyst Pharmaceuticals is owned by 82.75% institutional investors, 6.20% insiders, and 11.05% retail investors. Blackrock is the largest institutional shareholder, holding 16.01% of CPRX shares. iShares Core S&P Small-Cap ETF is the top mutual fund, with 5.57% of its assets in Catalyst Pharmaceuticals shares.

CPRX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockCatalyst Pharmaceuticals82.75%6.20%11.05%
SectorHealthcare Stocks 487.91%11.08%-398.99%
IndustryBiotech Stocks 307.10%11.11%-218.21%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock18.69M16.01%$289.58M
Blackrock funding, inc. /de18.90M15.47%$410.14M
Vanguard group8.43M7.09%$175.96M
State street5.80M4.87%$120.97M
Dimensional fund advisors lp3.01M2.53%$62.88M
Deerfield management company, l.p. (series c)2.88M2.36%$62.48M
Goldman sachs group2.80M2.36%$58.49M
Renaissance2.71M2.28%$56.48M
Geode capital management2.67M2.24%$55.64M
Fundsmith llp2.71M2.22%$58.79M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Tanaka capital management153.29K7.31%$3.20M
Gables capital management409.02K4.20%$8.88M
Jw asset management388.39K4.15%$8.43M
Knott david m jr176.00K1.73%$3.82M
Qsv equity investors53.44K1.21%$1.16M
Mesirow institutional investment management742.29K1.19%$15.49M
Deerfield management company, l.p. (series c)2.88M1.13%$62.48M
Ikarian capital209.65K0.87%$4.55M
Hussman strategic advisors147.00K0.73%$3.19M
Pvg asset management11.79K0.72%$182.56K

Top Buyers

HolderShares% AssetsChange
Goldman sachs group2.80M0.01%1.33M
American century companies1.76M0.02%1.23M
Blackrock18.69M0.01%962.28K
Macquarie group682.65K0.02%682.65K
Fundsmith llp2.71M0.26%557.81K

Top Sellers

HolderShares% AssetsChange
Morgan stanley1.01M0.00%-786.18K
Point72 asset management---618.30K
Deerfield management company, l.p. (series c)2.88M1.13%-542.67K
Brandywine global investment management---392.12K
Deutsche bank ag\200.40K0.00%-377.81K

New Positions

HolderShares% AssetsChangeValue
Macquarie group682.65K0.02%682.65K$14.25M
Orbimed advisors416.90K0.23%416.90K$9.05M
Wedge capital management l l p/nc145.17K0.05%145.17K$2.86M
Norges bank91.77K0.00%91.77K$1.92M
Glenmede investment management, lp77.14K0.01%77.14K$1.67M

Sold Out

HolderChange
Global financial private client-1.00
Coppell advisory solutions-8.00
Mendota financial group-12.00
Richards, merrill & peterson-15.00
Aspire private capital-20.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 2025354-3.54%101,094,7563.01%821.27%2043.55%118-2.48%
Mar 31, 20253616.80%97,419,101-0.16%801.19%193-4.46%11933.71%
Dec 31, 20243294.44%99,023,9753.92%831.30%19521.88%87-17.14%
Sep 30, 202431314.65%95,228,606-1.82%801.16%15925.20%10418.18%
Jun 30, 2024270-96,978,1880.88%831.02%126-20.75%8726.09%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
iShares Core S&P Small-Cap ETF6.82M5.57%-
Vanguard Total Stock Mkt Idx Inv3.63M2.97%-77.47K
Vanguard US Total Market Shares ETF3.55M2.91%3.78K
iShares Russell 2000 ETF2.78M2.27%-
Smithson Investment Trust Ord2.71M2.21%-
First Trust NYSE Arca Biotech ETF1.89M1.59%-
Avantis US Small Cap Value ETF1.80M1.47%14.54K
Vanguard Institutional Extnd Mkt Idx Tr1.23M1.01%-534.49K
SPDR® S&P Biotech ETF1.17M0.95%2.60K
Fidelity Small Cap Index1.16M0.95%15.51K

Recent Insider Transactions


DateNameRoleActivityValue
Sep 08, 2025Elsbernd Brian Chief Compliance/Legal OfficerSell$609.00K
Sep 04, 2025Elsbernd Brian Chief Compliance/Legal OfficerSell$585.60K
Sep 03, 2025Elsbernd Brian Chief Compliance/Legal OfficerSell$401.60K
Aug 27, 2025Tierney David S-Sell$525.20K
Aug 26, 2025Miller Steve Chief Op. & Scientific OfficerSell$2.33M

Insider Transactions Trends


DateBuySell
2025 Q3-6
2025 Q2-7
2025 Q1-5
2024 Q4-14
2024 Q3-7

CPRX Ownership FAQ


Who Owns Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals shareholders are primarily institutional investors at 82.75%, followed by 6.20% insiders and 11.05% retail investors. The average institutional ownership in Catalyst Pharmaceuticals's industry, Biotech Stocks , is 307.10%, which Catalyst Pharmaceuticals falls below.

Who owns the most shares of Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals’s largest shareholders are Blackrock (18.69M shares, 16.01%), Blackrock funding, inc. /de (18.9M shares, 15.47%), and Vanguard group (8.43M shares, 7.09%). Together, they hold 38.57% of Catalyst Pharmaceuticals’s total shares outstanding.

Does Blackrock own Catalyst Pharmaceuticals?

Yes, BlackRock owns 16.01% of Catalyst Pharmaceuticals, totaling 18.69M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 289.58M$. In the last quarter, BlackRock increased its holdings by 962.28K shares, a 5.43% change.

Who is Catalyst Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Tanaka capital management is Catalyst Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 7.31% of its assets in 153.29K Catalyst Pharmaceuticals shares, valued at 3.2M$.

Who is the top mutual fund holder of Catalyst Pharmaceuticals shares?

iShares Core S&P Small-Cap ETF is the top mutual fund holder of Catalyst Pharmaceuticals shares, with 5.57% of its total shares outstanding invested in 6.82M Catalyst Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools